Literature DB >> 6980048

Sequential methotrexate and 5-FU in the treatment of colorectal cancer.

B Weinerman, B Schacter, H Schipper, D Bowman, M Levitt.   

Abstract

Administration of methotrexate (MTX), 5-FU, and leucovorin rescue in 29 patients with metastatic colorectal cancer produced an objective response rate of 41.7%, with two complete remissions. Two patients developed fatal toxic effects and three others had severe toxic effects. This trial, however, supports the evidence for the synergistic effect of this drug combination.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6980048

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  3 in total

1.  A phase II study of sequential methotrexate and 5-fluorouracil in colorectal carcinoma.

Authors:  M J Harding; S B Kaye; M Soukop; J C Ferguson
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

2.  Sequential methotrexate (MTX) and 5-fluorouracil (FU) in human tumor xenografts.

Authors:  K Wayss; R Herrmann; J Mattern; M Volm
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

3.  Methotrexate and 5-fluorouracil in the treatment of squamous and other carcinomas of the head and neck.

Authors:  D J Stewart; J A Maroun; C Cripps; V Young; G Laframboise; J Gerin-Lajoie
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.